Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Aldeyra Therapeu (NQ: ALDX)
5.150 USD  -0.020 (-0.39%)
Streaming Delayed Price  /  Updated: 11:24 AM EST, Feb 19, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 38,764
Open 5.180
Bid (Size) 5.140 (7)
Ask (Size) 5.150 (3)
Prev. Close 5.170
Today's Range 5.140 - 5.240
52wk Range 4.310 - 12.79
Shares Outstanding 20,109,394
Dividend Yield N/A
Performance
YTD
-13.59%
-13.59%
1 Month
-17.60%
-17.60%
3 Month
-14.59%
-14.59%
6 Month
+0.98%
+0.98%
1 Year
-32.41%
-32.41%
Top News
More News
Aldeyra Therapeutics to Host 2020 Research & Development Day
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... Read More
from Business Wire News Releases
Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board
Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board Read More
from Business Wire News Releases
More News
Read More
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
from Business Wire News Releases
Aldeyra Therapeutics Appoints Nancy Miller-Rich to Board of Directors
from Business Wire News Releases
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy
from Business Wire News Releases
Implied IWN Analyst Target Price: $139
category ETFs
from ETF Channel
Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
from Business Wire News Releases
Commit To Purchase Aldeyra Therapeutics At $5, Earn 39.8% Annualized Using Options
category Stocks
from Market News Video
Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
from Business Wire News Releases
Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences
from Business Wire News Releases
How The Pieces Add Up: VXF Targets $136
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.